公开(公告)号：US20220193214A1

公开(公告)日：2022-06-23

申请号：US17532217

申请日：2021-11-22

申请人： Qingdao Bolin Biological Technology Co., Ltd.

发明人： Yongda Zhao ,  Lili Guo ,  Lihua Ma

IPC分类号： A61K39/112 ,  A61K39/108 ,  A61K39/02 ,  A61P31/04

摘要： The present disclosure belongs to the technical field of veterinary biological products, and specifically relates to a triple vaccine for diseases caused by Salmonella typhimurium, Riemerella anatipestifer and Escherichia coli. In the triple vaccine, antigens are an inactivated Salmonella typhimurium E01 strain, an inactivated Riemerella anatipestifer R01 strain and an inactivated Escherichia coli E01 strain. The three strains used in the vaccine have high virulence, disable immunogenicity and disable cross-protection. The prepared vaccine has a desirable safety, causing no local or systemic adverse reactions. In a shelf life test, all indicators of the vaccine are stable and effective after a data analysis of traits, a safety test and an efficacy test; in addition, efficacy test results prove that the inactivated triple vaccine can produce desirable antibodies and relatively desirable attacking protection.

公开(公告)号：US11883477B2

公开(公告)日：2024-01-30

申请号：US17532217

申请日：2021-11-22

申请人： Qingdao Bolin Biological Technology Co., Ltd.

发明人： Yongda Zhao ,  Lili Guo ,  Lihua Ma

IPC分类号： A61K39/112 ,  A61P31/04 ,  A61K39/02 ,  A61K39/108 ,  A61K39/00

CPC分类号： A61K39/0275 ,  A61K39/0208 ,  A61K39/0258 ,  A61P31/04 ,  A61K2039/521 ,  A61K2039/70

摘要： The present disclosure belongs to the technical field of veterinary biological products, and specifically relates to a triple vaccine for diseases caused by Salmonella typhimurium, Riemerella anatipestifer and Escherichia coli. In the triple vaccine, antigens are an inactivated Salmonella typhimurium S01 strain, an inactivated Riemerella anatipestifer R01 strain and an inactivated Escherichia coli E01 strain. The three strains used in the vaccine have high virulence, disable immunogenicity and disable cross-protection. The prepared vaccine has a desirable safety, causing no local or systemic adverse reactions. In a shelf life test, all indicators of the vaccine are stable and effective after a data analysis of traits, a safety test and an efficacy test; in addition, efficacy test results prove that the inactivated triple vaccine can produce desirable antibodies and relatively desirable attacking protection.